The Cancer Researcher Who Became His Own Patient: Richard Scolyer's Legacy

Professor Richard Scolyer AO died in 2026 at age 59, nearly three years after being diagnosed with glioblastoma — a severe form of brain cancer — in June 2023. He was one of the world's leading experts on melanoma, and when he fell ill, he did something extraordinary: he used himself as the first test subject for an experimental treatment based on his own life's work.

Building the Foundation for a Melanoma Breakthrough

Scolyer spent his career at the core of Australia's melanoma research infrastructure. Starting in 2001, he helped establish and maintain the world's largest collection of melanoma tissue samples — essentially a vast library of cancer specimens. These samples, first gathered in 1998, allowed scientists to understand how different melanomas vary at the genetic level.

His main clinical job was at Royal Prince Alfred Hospital in Sydney, where he was a senior specialist in tissue pathology. He also taught at the University of Sydney and worked closely with collaborator Professor Georgina Long at Melanoma Institute Australia. By 2019, Thomson Reuters ranked him as the world's top publisher in melanoma pathology research — a measure of how many influential papers he had authored.

The field recognized this standing. In 2023, he received major awards from the American Society of Dermatopathology and the International Academy of Pathology. The following January, Prime Minister Anthony Albanese named him and Long as 2024 Australians of the Year.

The Revolution He Helped Create

Here's why Scolyer's standing matters. Less than a decade before 2024, advanced melanoma was essentially a death sentence. Then came checkpoint inhibitors — a new class of cancer drugs that work by releasing the brakes on the immune system so it can attack tumors. Scolyer and Long's work on understanding melanoma at a cellular level was central to making these drugs work. Within roughly ten years, advanced melanoma went from almost always fatal to curable in many patients. That is a rapid reversal in modern cancer medicine.

The broader context here is that this success gave Scolyer and Long something rare: the credibility and the track record to attempt something that had never been tried before.

Becoming the First Patient

When Scolyer was diagnosed with glioblastoma in June 2023, the standard treatment options were surgery, radiation, and chemotherapy. Median survival is measured in months, not years. But instead of following the conventional path alone, Scolyer and Long designed an experimental protocol based on the same immunotherapy principles that had worked for melanoma.

He became the world's first brain cancer patient to receive combination immunotherapy before surgery as an experimental treatment, according to Australian of the Year records. The regimen included a personalized cancer vaccine — designed specifically to target the genetic markers of his individual tumor rather than treating glioblastoma as a one-size-fits-all disease. The idea was borrowed from his melanoma work: prime the immune system with therapy before surgery, and you might get a stronger, longer-lasting response.

The treatment did not cure him. But it extended his life and, more importantly, it produced data. That data was enough to launch an early-stage clinical trial in the United States, as reported by the BBC. The trial is still running.

This echoes a famous precedent: when Barry Marshall and Robin Warren were trying to prove that bacteria caused stomach ulcers, Marshall drank a bacterial solution himself to accelerate acceptance of their discovery. The diseases and mechanisms are entirely different, but the logic is similar — sometimes the fastest way past institutional skepticism is to use yourself as evidence.

Recognition and Farewell

In April 2026, just weeks before his death, the University of Sydney awarded Scolyer an honorary doctorate while he was alive to receive it, per the University's record. Before he died, he published an open letter thanking Australians for their support during his illness — characteristically direct, reflecting how he had communicated publicly about his diagnosis from the start.

The Work Continues

Scolyer's death does not end the science. The U.S. clinical trial his protocol initiated is still active. Georgina Long continues as co-medical director of Melanoma Institute Australia and leads the work forward.

The trial is now testing whether the immunological approach that transformed melanoma treatment can work for glioblastoma. The challenge is substantial. The brain has natural barriers — the blood-brain barrier — that keep immune cells out as a protective measure. The tumor's microenvironment suppresses immune activity. And different glioblastomas have different mutations, making one-size-fits-all approaches difficult. Scolyer's protocol tried to address these problems by priming the immune system before surgery and personalizing the vaccine to each tumor's genetic signature.

Whether this approach will work in other patients with different tumor profiles is an open question. That is precisely what the trial is designed to answer — or at least begin to. The contribution Scolyer left behind is not a finished proof, but a rigorously designed hypothesis, now being tested on the scale and terms he established.

Melanoma Institute Australia published a formal tribute following his death. He was 59.